EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Azvudine versus Paxlovid in COVID‐19: A systematic review and meta‐analysis

Behnam Amani, Bahman Amani iD

Reviews in Medical Virology · 2024

DOI: 10.1002/rmv.2551 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Reviews in Medical Virology, 2024. Verfasst von Behnam Amani und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment, Antiviral Agents, SARS-CoV-2, Ritonavir. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This systematic review and meta‐analysis aimed to compare the effectiveness and safety of azvudine versus nirmatrelvir/ritonavir (Paxlovid) in treating coronavirus disease 2019 (COVID‐19). The researchers conducted searches on PubMed, Cochrane Library, Web of Science, medRxiv, and Google Scholar until January 2024. The Cochrane risk of bias tool was utilised to evaluate the quality of the included studies, and data analysis was performed using Comprehensive Meta‐Analysis software. Thirteen studies, including 4949 patients, were analysed. The meta‐analysis results showed no significant difference between the azvudine and Paxlovid groups in terms of mortality rate (odds rate [OR] = 0.84, 95% confidence interval [CI]: 0.59–1.21), negative polymerase chain reaction (PCR) conversion time (standard mean difference [SMD] = 1.52, 95% CI: −1.07–4.11), and hospital stay (SMD = −0.39, 95% CI: −1.12–0.33). However, a significant difference was observed between the two groups in terms of intensive care unit admission (OR = 0.42, 95% CI: 0.23–0.75) and the need for mechanical ventilation (OR = 0.61, 95% CI: 0.44–0.86) in favour of azvudine. The incidence of adverse events in the azvudine group was significantly lower (OR = 0.66, 95% CI: 0.43–0.99). The certainty of evidence was rated as low and moderate. Azvudine and Paxlovid demonstrated similar effectiveness in reducing mortality rates, negative PCR conversion time and hospital stay. However, azvudine showed better effectiveness in improving other outcomes. Regarding the level of certainty of evidence, further research is needed to validate or challenge these results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19 Drug TreatmentAntiviral AgentsSARS-CoV-2RitonavirDrug CombinationsHumansCOVID-19LopinavirTreatment Outcome

Stichwörter der Autor:innen

COVID‐19PaxlovidSARS‐COV‐2azvudinenirmatrelvir/ritonavir

Substanzen

Antiviral AgentsRitonavirDrug CombinationsLopinavirlopinavir-ritonavir drug combination

Autor:innen und Institutionen

  • Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Bahman Amani

Zitieren

APA

Amani, B., & Amani, B. (2024). Azvudine versus Paxlovid in COVID‐19: A systematic review and meta‐analysis. Reviews in Medical Virology. https://doi.org/10.1002/rmv.2551

Vancouver

Amani B, Amani B. Azvudine versus Paxlovid in COVID‐19: A systematic review and meta‐analysis. Reviews in Medical Virology. 2024. doi:10.1002/rmv.2551

BibTeX
@article{Amani2024,
  author = {Amani, Behnam and Amani, Bahman},
  title = {Azvudine versus Paxlovid in COVID‐19: A systematic review and meta‐analysis},
  journal = {Reviews in Medical Virology},
  year = {2024},
  doi = {10.1002/rmv.2551}
}
Kostenlos starten →